The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. The results are published in the New England Journal of Medicine.
This article was originally published on MedicalXpress.com

